CME Presentations
Integrating a Risk‐Stratified Approach to Treating Patients with Upper Tract Urothelial Carcinoma: A Serial Educational Initiative for the Uro‐Oncology Team
Presentations
Refining Risk-Based Treatment Decisions in the Era of Kidney-Sparing Options for Upper Tract Urothelial Carcinoma
Speakers: Phillip M. Pierorazio, MD, Associate Professor of Urology and OncologyNeal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center Duration: 60 minutes
Presented on: June 16, 2020
Addressing Real-World Challenges of Integrating Novel Therapies for Patients with Upper Tract Urothelial Carcinoma
Speakers: Phillip M. Pierorazio, MD, Associate Professor of Urology and OncologyNeal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center Duration: 60 minutes
Presented on: December 8, 2020
Speakers
Phillip M. Pierorazio, MD
Phillip M. Pierorazio, MD
Associate Professor of Urology and Oncology
Phillip M. Pierorazio, MD, is associate professor of urology and oncology in the Brady Urological Institute at Johns Hopkins University in Baltimore, Maryland. He has expertise in all malignancies of the urinary tract and performs open and minimally-invasive surgeries of the kidney, bladder, prostate and retroperitoneal lymph node dissection for testicular cancer. He has a special interest in kidney cancer, including partial nephrectomy for early-stage disease and high-risk surgeries for patients with advanced cancers. Dr Pierorazio is on the AUA and NCCN Guidelines Committees for Kidney Cancer, director of the Division of Testicular Cancer and a member of the NCCN Guidelines Committee and works with various testicular cancer advocacy groups around the United States.Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS
Medical Director, Carolina Urologic Research Center
Neal D. Shore, MD, FACS, is the medical director for the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr Shore has conducted more than 350 clinical trials that focus mainly on GU oncology, has served on the executive boards of the Society of Urologic Oncology, Bladder Cancer Advocacy Network and the Society of Urologic Oncology Clinical Trials Consortium, and is immediate past president of the Large Urology Group Practice Association. He is a founder for the CUSP Clinical Trials Consortium and DASHKO, large urology practices data registries. He has over 150 peer-reviewed publications, several book chapters, and is a peer reviewer for numerous high-impact medical journals. He earned his MD from Duke University Medical School and general surgery/urology residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center.
CME Information
Refining Risk-Based Treatment Decisions in the Era of Kidney-Sparing Options for Upper Tract Urothelial Carcinoma
LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
- Integrate diagnostic techniques to improve grading and risk stratification of UTUC
- Review guideline-based and expert recommended endoscopic diagnosis and management of UTUC
- Differentiate kidney-sparing treatment strategies for low-grade vs high-grade UTUC
- Assess the safety and efficacy of current and emerging risk-based treatment approaches and facilitate clinical integration of novel treatment approaches
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLCACKNOWLEDGEMENT
This activity is supported by an educational grant from UroGen Pharma.TUITION
Complimentary
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.LIVE CREDIT DESIGNATION STATEMENTS
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Refining Risk-Based Treatment Decisions in the Era of Kidney-Sparing Options for Upper Tract Urothelial Carcinoma
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2098-L04-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hours.
Enduring Credit Designation Statements
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Refining Risk-Based Treatment Decisions in the Era of Kidney-Sparing Options for Upper Tract Urothelial Carcinoma
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2099-H04-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hours.
Date of Release/Expiration
Live Activity
Tuesday, June 16, 2020 from 12:00 PM EST – 1:00 PM EST
Enduring Material:
• Refining Risk-Based Treatment Decisions in the Era of Kidney-Sparing Options for Upper Tract Urothelial Carcinoma: The enduring material will be available from June 16, 2020 to December 8, 2021
TARGET AUDIENCE
Urologists, genitourinary and medical oncologists, pharmacists, and other health care professionals on the uro-oncology team involved in the management of patients with UTUC.ESTIMATED TIME TO COMPLETE
This activity consists of one session which should take approximately 1 hour to complete.METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.UroCareLive.com or www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test. For Pharmacists: Upon receipt of the completed activity evaluation form credit will be submitted to the NABP CPE Monitor Service. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.nabp.net.HARDWARE / SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Neal Shore, MD, FACS
Medical Director, CPI
Carolina Urologic Research Center
Atlantic Urology ClinicsConsulting Fees: Abbvie, Amgen, Astellas, AZ, Bayer, BMS, Clovic Oncology, Dendreon, Fergene, Ferring, Janssen, Merck, MDX, Myovant, Nymox, Pfizer, Sanofi Genzyme, Tolmar Phillip M. Pierorazio, MD
Associate Professor of Urology and Oncology
Brady Urological Institute and Department of Urology, Johns Hopkins MedicineConsulting Fee: Urogen Pharma
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLCNone
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact UroCareLive at 877-394-1306 or at Support@UroCareLive.com or OMedLive at 877-394-1306 or at Support@OMedLive.com.
